Pharmacogenetics of hypertension: randomized monocentric study in patients with essential hypertension and treated with Spironolactone or Torasemide - Pharmacogenetics of hypertension: study with Spironolactone or Torasemide

OSPEDALE SAN RAFFAELE0 sites144 target enrollmentOctober 21, 2020

Overview

No summary available.

Registry

who.int

Start Date

October 21, 2020

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

OSPEDALE SAN RAFFAELE

•a. male patients aged 25\-65 years and female patients aged 45\-65 years in menopause
•b. naïve hypertensive patients (newly diagnosed, never previously treated) or in therapy with a single anti\-hypertensive drug
•c. documented hypertension of grade I or II (according to ESH 2013 guidelines, in the untreated patient or despite the therapy).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 144
•F.1\.3 Elderly (\>\=65 years) no
•F.1\.3\.1 Number of subjects for this age range

•a. known causes of secondary hypertension
•b. stage II hypertension (SBP \= 180 and DBP \= 110 mmHg;
•c. history of renal artery stenosis
•d. significant kidney disease (eGFR\-CK\-EPI less than 60 ml/min)
•e. refractory hypokalaemia or hyponatraemia (plasma Na \< 126 mEq/L)
•f. hyperkalaemia (plasma K \> 5\.5 mEq/L)
•g. hypercalcaemia
•h. symptomatic hyperuricemia
•i. liver disease (transaminases greater than 3 times the maximum laboratory value)
•j. cardiac pathologies (previous myocardial infarction, ongoing atrial fibrillation, etc.)